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Abstract
Introduction
In the United States, tobacco use is the leading pre-
ventable cause of death and disease. The health and
cost consequences of tobacco dependence have made
treatment and prevention of tobacco use a key priority
among multiple stakeholders, including health plans,
insurers, providers, employers, and policymakers. In
2002, the third survey of tobacco control practices and
policies in health plans was conducted by America’s
Health Insurance Plans’ technical assistance office as
part of the Addressing Tobacco in Managed Care
(ATMC) program. 
Methods
The ATMC survey was conducted in the spring of 2002
via mail, e-mail, and fax. A 19-item survey instrument
was developed and pilot-tested. Of the 19 items, 12 were
the same as in previous years, four were modified to col-
lect more detailed data on areas of key interest, and
three were added to gain information about strategies to
promote smoking cessation. The sample for the survey
was drawn from the 687 plans listed in the national
directory of member and nonmember health plans in
America’s Health Insurance Plans. 
Results
Of the 246 plans in the sample, 152 plans (62%) repre-
senting more than 43.5 million health maintenance organ-
ization members completed the survey. Results show that
health plans are using evidence-based programs and clin-
ical guidelines to address tobacco use. Compared to ATMC
survey data collected in 1997 and 2000, the 2002 ATMC
survey results indicate that more health plans are provid-
ing full coverage for first-line pharmacotherapies and tele-
phone counseling for smoking cessation. Plans have also
shown improvement in their ability to identify at least
some members who smoke. Similarly, a greater percent-
age of plans are employing strategies to address smoking
cessation during the postpartum period to prevent smok-
ing relapse and during pediatric visits to reduce or elimi-
nate children’s exposure to environmental tobacco smoke. 
Conclusion
The results of the 2002 ATMC survey reflect both
tremendous accomplishments and important opportuni-
ties for health plans to collaborate in tobacco control
efforts. With appropriate support, analytical tools, and
resources, it is likely that health plans, clinicians,
providers, and consumers will continue to evolve in their
efforts to reduce the negative consequences of tobacco use.
Introduction
In the United States, tobacco use is the leading prevent-
able cause of death and disease. Smoking kills more than
440,000 people in the United States each year, with most
deaths occurring from lung cancer, ischemic heart disease,
and chronic airway obstruction (1). Yet approximately 23%
of American adults continue to smoke cigarettes (2). In
2000, it was estimated that approximately 8.6 million per-
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sons in the United States were living with at least one con-
dition attributed to smoking (3).
The health consequences of tobacco use are accompanied
by a staggering economic burden. Smoking caused more
than $157 billion in annual health-related economic losses
between 1995 and 1999, including $81.9 billion in smok-
ing-related productivity losses and $75.5 billion in excess
medical expenditures (1). Smoking-attributable neonatal
expenditures were estimated at $366 million in 1996, or
$704 per maternal smoker (1). Together, the consequences
and costs of tobacco dependence have made treatment and
prevention of tobacco use a key priority among multiple
stakeholders, including health plans, insurers, providers,
employers, and policymakers. 
In 1997, The Robert Wood Johnson Foundation estab-
lished a collaborative program, Addressing Tobacco in
Managed Care (ATMC). This program is based on the
understanding that health plans’ comprehensive benefits,
sophisticated information systems, and defined popula-
tions, as well as their ongoing partnerships with health
care providers, are well suited to implement, evaluate, and
sustain tobacco control interventions. ATMC includes a
National Program Office based at the University of
Wisconsin Medical School’s Center for Tobacco Research
and Intervention, and a national technical assistance
office (NTAO) managed by America’s Health Insurance
Plans (AHIP), formerly known as the American
Association of Health Plans (AAHP). The mission of the
NTAO is to advance the integration of tobacco cessation
and prevention programs into routine health care by
increasing the number and quality of tobacco control ini-
tiatives within health plans.
The NTAO provides resources to health plans and insur-
ers striving to develop tobacco control programs; conducts
a benchmarking awards program to highlight exemplary
health plan tobacco control initiatives; promotes best prac-
tices and partnerships through national conferences; and
oversees the development of a business case model for
smoking cessation. The NTAO has also conducted three
surveys of health plans over the past six years to assess
practices and policies related to tobacco control. 
The ATMC baseline survey was conducted in 1997, fol-
lowed by a similar survey in 2000. The results of both sur-
veys were published in peer-reviewed journals in 1998 and
2002 (4,5). The purpose of this paper is to present the
results of the 2002 ATMC survey; highlight changes from
1997 to 2002; cross-reference the findings with national
guidelines and recommendations; and explore these find-
ings and trends in light of the changing environment in
which health plans operate and the public’s attitude
toward tobacco use.
Methods
A 19-item survey instrument was developed and pilot-
tested in the fall of 2001. The instrument was designed to
assess new trends, barriers, and opportunities related to
addressing tobacco control in health plans, identify new
models or frameworks of care, and assess changes in
health-plan–based tobacco control activities between 1997
and 2002. The sample for the survey was drawn from the
687 plans listed in AHIP’s national directory of member
and nonmember health plans. The directory was stratified
based on health plan enrollment size, and a random sam-
ple of 246 health plans was selected. The sample size
enables the detection of a 5% difference between propor-
tions at a = .05 and ß = .80. 
The ATMC survey was conducted in the spring of 2002.
As in 1997 and 2000, the 2002 survey was conducted via
mail, e-mail, and fax, with telephone follow-up with non-
respondents at two, four, and six weeks after initial con-
tact. The sample included large national plans that have
local plans in multiple states. As in previous years, the cor-
porate office of each national plan was asked to review the
questionnaire and determine whether they would respond
on behalf of their local plans or ask local plans to complete
the questionnaires individually. Three of four national
plans opted to respond on behalf of their local plans and
their responses reflect 64% (97/152) of the responses. 
The 2002 survey questionnaire was similar to the 2000
survey. Of the 19 items in the 2002 questionnaire, 12 were
the same as in previous years, four were modified to collect
more detailed data on areas of key interest (i.e., pharma-
ceutical coverage and system-level interventions), and
three were added to gain information about strategies to
promote smoking cessation. Based on feedback provided
during pretesting, the majority of survey questions focused
on smoking cessation despite recognition that tobacco ces-
sation or tobacco control is a more encompassing term.
Although we recognize that the preferred provider organi-
zation (PPO) product has grown in popularity, the 2002
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based on their best-selling commercial health mainte-
nance organization (HMO) product to preserve the ability
to make comparisons with previous years.
All analyses were performed with SPSS software (SPSS,
Inc, Chicago, Ill). Chi-square tests and t-tests were used
for comparisons, and results of these tests were considered
statistically significant when the corresponding P value
was # .05. Consistent with previous years, the data are
unweighted to best describe the policies and practices of
health plans.
Results
Of the 246 plans in the sample, 152 (62%) completed and
returned the survey. Collectively, the 152 plans represent
more than 43.5 million HMO members. Respondent plans
were predominantly independent practice association, net-
work, and mixed models. Fifty-one percent were for-profit
and publicly held; 24% were for-profit and privately held;
23% were not-for-profit; and 2% were mutual companies.
A comparative analysis of respondents and nonrespon-
dents to the 2002 survey indicated that there were no sig-
nificant differences in size, tax status, or predominant
model type between respondents and nonrespondents.
Among plans that responded to the 2002 ATMC survey,
71% reported having written clinical guidelines for smok-
ing cessation. The majority of plans reported having guide-
lines that had been internally developed by the plan; few
plans reported using the 2000 U.S. Public Health Service
Clinical Practice Guideline on Tobacco Use and
Dependence or the 1996 Agency for Health Care Policy and
Research (now the Agency for Healthcare Research and
Quality [AHRQ]) Practice Guideline on Tobacco Cessation
(Table 1). 
Nearly three quarters of all plans indicated that they
could identify at least some individual plan members who
smoke (Table 1). Among those plans that reported being
able to identify individual smokers, the most common data
sources are health risk appraisals and telephone inter-
views. Only 6% of plans use enrollment data to identify
individual smokers.
The vast majority of health plans that responded to the
survey reported that they provide full coverage for at least
one type of pharmacotherapy used for tobacco cessation
(Table 1). Bupropion, in the form of Wellbutrin, was the
most commonly covered pharmacotherapy. Only 11% of
plans reported that provision of full coverage for tobacco
cessation pharmacotherapies is dependent on enrollment
in a counseling or cessation program. 
Full coverage for at least one type of behavioral inter-
vention used for tobacco cessation was reported by the vast
majority of health plans (Table 1). Telephone counseling
was the most commonly covered behavioral intervention,
followed by face-to-face counseling and self-help materials. 
Health plans reported having a variety of strategies to
encourage members to stop smoking during times that
might be considered important teachable moments. The
majority of health plans reported having a specific strate-
gy to address smoking cessation during pregnancy and
during treatment for chronic illnesses (Table 1). 
Plans reported that a variety of strategies are used with
providers and their office staff to promote smoking cessa-
tion among plan members. The majority of plans reported
offering provider education and offering prompts and
reminders to providers (Table 1). Provider prompts and
reminders were coupled with provider education by 44% of
plans. Few plans reported offering incentives to providers
and their staff to promote smoking cessation. 
Health plans reported that they require providers to
carry out a variety of assessments and activities related to
smoking that are in accordance with the clinical model of
the 5 As: Ask, Advise, Assess, Assist, and Arrange (6).
(The 2002 ATMC survey was fielded before the develop-
ment of Assess willingness to quit.) The majority of plans
require providers to ask new patients about smoking sta-
tus and include smoking status as a vital sign (ask about
smoking status at every visit) (Table 1). Fewer plans
reported requiring providers to carry out activities aimed
at advising, assisting, and following up with patients try-
ing to quit smoking. 
Although health plans reported a variety of barriers that
limit their ability to effectively address tobacco control, the
most common barriers relate to resources (e.g., inadequate
staff, funding, competing priorities) and system issues (e.g.,
poor data collection, reporting, record maintenance). Other
barriers included lack of patient demand, lack of purchaser
demand, and delayed economic return on investment.
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Tobacco control activities used by larger health plans are
different from those used by smaller plans (Table 2). Based
on the enrollment distribution of health plans in our sam-
ple, we defined larger plans as those with more than
250,000 members and smaller plans as those with less
than or equal to 250,000 members. Larger plans were
more likely than smaller plans to have written clinical
guidelines for smoking cessation (P < .001) and to have a
specific strategy to address smoking cessation during spe-
cific times, such as adolescence, pregnancy, postpartum
visits, and hospitalization (P ranged from < .001 to .02).
Smaller plans, more likely to be staff and group-model
plans, were more likely to be able to identify individual
plan members who smoke (P < .001) and provide full cov-
erage for some prescription pharmacotherapies used for
smoking cessation (P ranged from <.001 to .02). 
Although the ATMC survey instruments used in 1997,
2000, and 2002 were not identical, the majority of core
questions on pharmacotherapies, behavioral health, and
smoking cessation strategies remained unchanged. The
percentage of plans that provide full coverage for any type
of pharmacotherapy used for smoking cessation more
than tripled from 1997 to 2002 (P < .001) (Table 3). The
percentage of plans able to identify individual smokers
also increased (P < .001). More plans reported providing
full coverage for telephone counseling (P = .04) and face-
to-face counseling (P = .011) in 2002 compared with both
previous surveys. 
From 1997 to 2002, there were large increases in the
percentage of plans with strategies to address relapse pre-
vention during the postpartum period (P = .02) and smok-
ing cessation during treatment for chronic illness (P =
.002) and following a heart attack (P = .004) (Table 3). 
Health plan performance on measures related to requir-
ing providers to adhere to four of the 5 As varied in both
directions between 2000 and 2002 (Table 3). Although
comparable data on these variables were not collected in
1997, the percentage of plans that require providers to ask
new patients about smoking status (P = .02) and strongly
advise all smokers to quit (P = .02) decreased from 2000 to
2002, and the percentage of plans that require providers to
include smoking as a vital sign (i.e., ask about it at every
visit) (P = .28) and assist smokers by referring them into
appropriate treatment (P = .33) increased modestly. 
Discussion
The results of the 2002 ATMC survey indicate that
health plans are using evidence-based programs and clin-
ical guidelines to address tobacco use. Clinical guidelines
detail the most effective options for helping patients to
quit smoking, and using strategies recommended in clini-
cal guidelines is associated with greater success in help-
ing smokers to quit (6,7). Although a large percentage of
health plans reported having written clinical guidelines
for tobacco cessation, it is possible that even more plans
address tobacco cessation within other clinical guidelines
used for managing or treating conditions in which tobac-
co use is identified as a comorbidity or risk factor (e.g.,
heart disease, diabetes, asthma). It is also noteworthy
that more than half of the plans reported adopting inter-
nally developed guidelines, as opposed to guidelines
developed by federal agencies and expert panels such as
the U.S. Public Health Service (USPHS) and AHRQ.
However, it is possible that plans reviewed such guide-
lines and integrated many or all of the key components
into their own guidelines. 
Plans showed remarkable improvement in 2002, com-
pared with previous years, in identifying individual plan
members who smoke. The ability to identify smokers is an
important indicator of a plan’s ability to remind or prompt
providers to discuss and/or advise patients about smoking
cessation. Such provider reminders are considered an
effective strategy for supporting smoking cessation and
are recommended by the Task Force on Community
Preventive Services (7). The survey question, however,
assesses the percentage of plans that can identify any
members who smoke (rather than all members who
smoke), and the methods that plans report using to identi-
fy smokers are most likely to identify subgroups of smok-
ers (i.e., those that respond to health risk appraisals or
surveys). Indeed, the ability of health plans to identify
smokers is contingent upon members actively providing
information about their smoking status during some inter-
action with the health plan, whether during enrollment,
through a survey, or via some other point of contact. 
The number of health plans providing full coverage for
any type of pharmacotherapy for tobacco cessation more
than tripled in 2002, compared with previous years. In the
2002 ATMC survey, nearly nine out of 10 plans reported
providing full coverage for at least one type of pharma-
cotherapy for tobacco cessation. Consistent with recom-
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tion and over-the-counter tobacco cessation first-line phar-
macotherapies (6), the majority of plans reported provid-
ing full coverage for bupropion. The significant increase in
the number of plans that provide full coverage for at least
one type of pharmacotherapy related to tobacco cessation
is well aligned with the growing body of literature indicat-
ing that reduced out-of-pocket cost is associated with
greater use of tobacco cessation programs and services (8-
12) and may lead to increased rates of cessation (10,11).
Consistent with literature citing the effectiveness of
telephone counseling and that smokers are more likely
to use telephone counseling than to participate in indi-
vidual or group counseling sessions (13,14), approxi-
mately half of plans surveyed provide full coverage for
telephone counseling. It is possible that even more
smokers have access to telephone counseling through
the availability of state-sponsored quit lines. Less than
25% of plans impose an annual or lifetime limit on cov-
erage for tobacco cessation treatments, indicating wide-
spread acceptance of the USPHS guideline recommend-
ing coverage for repeated, intensive tobacco dependence
counseling and pharmacotherapy (6). 
The results of the 2002 ATMC survey also suggest that
plans are paying close attention to pregnancy and the
postpartum period to assist women to quit smoking. The
large percentage of plans reporting strategies to address
smoking cessation during and after pregnancy to pre-
vent relapse may reflect greater health plan awareness
of research that has demonstrated the cost-effectiveness
of offering smoking cessation programs to pregnant
women (15).
Overall, our results indicate the greatest improvement
in tobacco control activities is at the health plan level as
opposed to the physician level. For example, more plans
report providing full coverage for pharmacotherapies than
report requiring providers to carry out activities in support
of the 5 As. This may be because most health plans (espe-
cially those that are not staff-model HMOs) find changing
physician behavior to be a challenge. Although more plans
are beginning to experiment with performance feedback as
a way to change physician behavior, prompts, reminders,
and provider training are more common strategies.
Health plans continue to report that resource limita-
tions, including insufficient staff and inadequate funding,
are leading barriers to adequately addressing tobacco con-
trol. Health plans may benefit from developing a business
case model that stresses the importance of tobacco cessa-
tion to purchasers and advocates for resources to imple-
ment and maintain evidence-based tobacco cessation pro-
grams. Research supported by the NTAO is underway to
provide an estimated return on investment for smoking
cessation interventions, based primarily on smoking-
attributable costs for health plans.
The ATMC survey and its findings have limitations. The
response rate of approximately 60% is respectable, but
leaves open the possibility of selection bias. Even though
no significant differences were detected between respon-
dents and nonrespondents on three key characteristics
(size, tax status, predominant model type), respondents
possibly differed from nonrespondents in ways that were
not measured. Another limitation to the ATMC survey is
that the psychometric properties of the questionnaire were
not tested to assess reliability or validity. However, the
survey design process did include substantial pretesting to
increase the probability of including questions that were
reliable and likely to yield valid responses. Additionally,
we identified a potential limitation of the 1997 survey — it
did not include a frame of reference for product type (e.g.,
HMO, PPO). When the survey does not specify product
type, respondents tend to answer for the HMO product.
Respondents were explicitly asked to answer for the HMO
product in 2000 and 2002. However, the possibility
remains that the change in frame of reference contributes
to some differences in survey findings from 1997 to 2000 or
2002 (but not from 2000 to 2002). 
Aside from the ATMC surveys, few surveys have
assessed tobacco control practices and policies of health
plans. Some surveys have focused on plans operating in a
single state (9,16), some have included a narrow subset of
plans (i.e., well-established nonprofit plans with a history
of offering tobacco cessation programs) (17), and others
have collected information about subsets of smokers with-
in a plan (i.e., pregnant women) (18,19). Nevertheless, a
1999 survey of California health plans reported results
comparable to our results: 85% of HMOs in the California
survey covered at least one form of pharmacotherapy; 77%
covered bupropion; 46% covered telephone counseling; and
54% covered individual counseling (16). However, the lim-
ited availability of comparable data prohibits comparisons
of our findings with other surveys and underscores the
importance of ATMC data for an adequate understanding
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of health plan tobacco control practices and policies at the
national level. 
The results of the 2002 ATMC survey indicate that an
increasing number of health plans are using evidence-
based approaches and strategies to address tobacco use.
However, in light of competing priorities for limited
resources, health plans may be challenged to sustain the
improvements they have made from 1997 to 2002. Cost
modeling and the development of a business case model for
smoking cessation may hold promise by assisting some
plans to leverage the body of literature that supports the
cost-effectiveness of tobacco cessation treatment (6,20-23). 
Just as challenges lay ahead, so do many important and
potentially exciting opportunities. Health plans are in a
key position to implement operational policies and pro-
grams that can reduce the prevalence of tobacco use and
positively impact the health of millions of individuals.
Health plans have the opportunity to sustain and expand
access to tobacco cessation treatments and services such as
pharmacotherapies and counseling services. As new evi-
dence emerges, health plans have the flexibility to model
new tobacco cessation benefits and promote them widely to
their membership. They also have the opportunity to influ-
ence large purchasers of health care services by communi-
cating the value of tobacco cessation services and expand-
ing their field of influence from the clinical and provider
setting to the broader community. By participating in com-
munity-wide campaigns and policy initiatives that support
tobacco cessation and prevention, stakeholders can influ-
ence and help control tobacco use. 
In summary, the results of the 2002 ATMC survey
reflect both tremendous accomplishments and important
opportunities for health plans to collaborate in tobacco
control efforts. With appropriate support, analytical tools,
and resources it is likely that health plans, clinicians,
providers, and consumers will continue to evolve in their
efforts to reduce the negative consequences of tobacco use. 
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% Yes
Plan has written clinical guidelines for smoking cessation 
Plan uses internally developed clinical guidelines for smoking cessation
Plan uses the 2000 U.S. Public Health Service Clinical Practice Guideline
Plan uses the 1996 Agency for Health Care Policy and Research Guideline
Plan uses guidelines from some other source
Plan is able to identify individual members who smoke
Health risk appraisal
Telephone survey
Sample of medical records
Administrative data review
71.1
56.6
5.3
3.3
5.9
71.7
89.9
74.1
60.6
53.2
Data sources used by plans to identify individual members who smoke (among plans that can identify smokers):
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Table 1. (continued)  Results from the 2002 Addressing Tobacco in Managed Care Survey (N = 152), United States
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% Yes
Mail-based survey
Electronic medical record
Enrollment information
Bupropion (as Wellbutrin) 
Bupropion (as Zyban)
Prescription NRTa nasal spray 
Prescription NRT inhaler 
NRT over-the-counter patches 
NRT over-the-counter gum 
Telephone counseling 
Face-to-face counseling 
Self-help materials (e.g., booklets, videos, audiotapes, tailored mailings) 
Individual counseling of pregnant women 
Group counseling or classes 
Plan has annual or lifetime limits on coverage for smoking cessation interventions 
Plan allows patients to self-refer to smoking cessation services
Ask new patients about their smoking status 
Include smoking status as a vital sign (i.e., ask about and document status at every visit) 
Strongly advise all patients who smoke to quit 
Refer smokers to intensive treatment as appropriate 
Arrange for follow-up with patients trying to quit smoking 
Pregnancy 
Treatment for other chronic illness 
Post-myocardial infarction 
Postpartum visits (relapse prevention) 
Adolescence 
Pediatric visits (secondhand smoke) 
Hospitalization 
Pregnancy 
Treatment for other chronic illness 
Post-myocardial infarction 
Adolescence 
48.6
48.6
6.4
79.2
41.1
35.8
35.8
8.6
4.6
51.7
41.1
25.8
19.2
15.9
15.1
59.3
61.2
54.3
44.1
33.6
30.3
56.6
52.0
46.7
46.7
28.9
28.3
7.2
65.1
61.8
57.2
57.2
Plan provides full coverage for:
Plan provides full coverage for:
Plan requires providers to:
Plan has specific strategy to address smoking cessation during:
Plan has guidelines, protocols, or pathways to address smoking cessation during:
(Continued on next page)Table 1. (continued)  Results from the 2002 Addressing Tobacco in Managed Care Survey (N = 152), United States
Table 2.  Tobacco Control Activities by Size of Health Plan: 2002 Addressing Tobacco in Managed Care Survey (N = 152),
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% Yes
Pediatric visits (secondhand smoke) 
Postpartum visits (relapse prevention) 
Hospitalization 
Plan funds a full- or part-time tobacco control program staff position 
Provider education
Providing prompts and reminders to encourage providers to address tobacco control 
Elimination of pre-authorization requirements for smoking cessation interventions 
Increased reimbursement for smoking cessation counseling/assistance
Incentives for providers and their staff to effectively address tobacco
Increased amount of time that providers can spend with patients
Resource barriers (e.g., staff, funding, competing priorities)
System barriers (e.g., poor data collection, reporting, record maintenance)
Lack of patient demand
Lack of purchaser demand 
Delayed economic return on investment 
55.3
53.3
36.2
19.1
69.8
53.2
40.1
34.2
4.6
<250,000 Members  >250,000 Members
(N = 102)  (N = 50) 
% Yes   % Yes   Pa 
Plan used the following strategies with providers and/or their office staff in the past year to promote smoking cessation:
Barriers limiting plan’s ability to address tobacco control:
aNRT indicates nicotine replacement therapy.
Plan has a written clinical guideline for smoking cessation 
NRTb over-the-counter gum
NRT over-the-counter patches
NRT inhaler 
NRT nasal spray 
Bupropion (as Zyban)
Bupropion (as Wellbutrin)
Telephone counseling
Face-to-face counseling
Group counseling or classes
62.4
3.0
7.9
42.6
42.6
47.5
80.0
62.4
52.5
14.9
90.0
8.0
10.0
22.0
22.0
28.0
77.6
30.0
18.0
18.0
<.001
.17
.67
.01
.01
.02
.73
<.001
<.001
.62
Plan provides full coverage for:
Plan provides full coverage for:
(Continued on next page)
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Table 2. (continued)  
Tobacco Control Activities by Size of Health Plan: 2002 Addressing Tobacco in Managed Care Survey (N = 152), United States
<250,000 Members  >250,000 Members
(N = 102)  (N = 50) 
% Yes   % Yes   Pa
Individual counseling of pregnant women
Self-help materials 
Plan has annual or lifetime limits on coverage for smoking 
cessation interventions 
Plan allows patients to self-refer to smoking cessation services 
Ask new patients about smoking status
Include smoking status as a vital sign (i.e., ask about and 
document status at every visit)
Strongly advise all patients who smoke to quit
Refer smokers to intensive treatment as appropriate
Arrange for follow-up with patients trying to quit smoking
Plan able to identify individual members who smoke 
Adolescence 
Pregnancy 
Postpartum visits (relapse prevention) 
Pediatric visits (secondhand smoke) 
Post-myocardial infarction 
Treatment for other chronic illness 
Hospitalization 
Adolescence 
Pregnancy 
Postpartum visits (relapse prevention) 
Pediatric visits (secondhand smoke) 
Post-myocardial infarction 
Treatment for other chronic illness 
Hospitalization 
Plan funds a tobacco control program staff position 
14.9
20.8
17.0
68.3
48.0
39.2
46.1
37.3
35.3
90.2
5.9
42.2
33.3
5.9
33.3
39.2
3.9
52.0
56.9
46.1
48.0
50.0
53.9
48.0
14.7
28.0
36.0
28.6
40.8
88.0
85.7
83.3
26.0
20.0
34.0
76.0
86.0
74.0
74.0
74.0
78.0
14.0
68.0
82.0
68.0
70.0
72.0
78.0
12.0
28.0
.054
.04
.10
.001
<.001
<.001
.001
.17
.054
<.001
<.001
<.001
<.001
<.001
<.001
<.001
.02
.06
.002
.01
.01
.01
.004
<.001
.05
Plan requires providers to:
Plan has a specific strategy to address smoking cessation during:
Plan has guidelines, protocols, or pathways to address smoking cessation during: 
aBoldface indicates a significant difference.
bNRT indicates nicotine replacement therapy.VOLUME 1: NO. 4
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Table 3.  Comparison of Data from the 1997, 2000, and 2002 Addressing Tobacco in Managed Care Surveys, United States
1997 2000 2002
(N = 323) (N = 85) (N = 152)
(% Yes)   (% Yes)   (% Yes)  Pa
Any pharmacotherapy for smoking cessation 
Zyban 
Any over-the-counter NRTb
NRT only with program enrollment 
Telephone counseling 
Face-to-face counseling 
Group counseling or classes 
Self-help materials 
Plan provides full coverage for any behavioral or pharmacotherapy
Ask new patients about smoking status 
Include smoking status as a vital sign (i.e., ask about and 
document status at every visit) 
Strongly advise all patients who smoke to quit 
Refer smokers to intensive treatment as appropriate 
Arrange for follow-up with patients trying to quit smoking 
Plan able to identify individual members who smoke 
Adolescence 
Pregnancy 
Postpartum visits (relapse prevention)
Pediatric visits (secondhand smoke)
Post-myocardial infarction 
Treatment for chronic illness 
Plan funds a full- or part-time tobacco control program staff 
position
25.0
17.6
6.6
25.0
32.8
26.6
35.7
54.1
75.0
NAc
NA
NA
NA
NA
14.9
17.6
45.0
13.6
15.8
21.7
22.6
7.7
59.2
37.2
14.9
26.0
36.8
23.6
37.0
56.6
94.4
74.1
43.5
68.3
24.7
36.5
27.1
24.2
59.0
30.5
17.3
27.2
31.3
23.5
88.8
41.1
8.6
10.8
51.7
41.1
15.9
25.8
98.0
61.2
54.3
44.1
33.6
30.3
71.7
28.9
56.6
46.7
28.3
46.7
52.0
19.1
<.001
.57
.004
.004
.04
.01
<.001
<.001
.28
.02
.28
.02
.33
.15
<.001
.46
.72
.02
.06
.004
.002
.15
Plan provides full coverage for:
Plan provides full coverage for:
Plan requires providers to:
Plan has a specific strategy to address smoking cessation during:
aBoldface indicates a significant difference.
bNRT indicates nicotine replacement therapy.
cNA indicates data not available because question was not included in 1997 ATMC survey.